^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) + Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
115P - Survival data from EMPOWER-Lung 4: Phase 2 study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small-cell lung cancer (NSCLC)
Published date:
03/17/2021
Excerpt:
...OS/PFS data shows that combination of ipilimumab 50 mg with cemiplimab 350 mg provides additional survival improvement in pts with advanced NSCLC and PD-L1 <50%.
Trial ID:
